No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
RDHL Redhill Biopharma
- 0.459
- +0.007+1.48%
Close May 7 16:00 ET
- 0.453
- -0.006-1.20%
Post 19:24 ET
14.62MMarket Cap0.11P/E (TTM)
0.470High0.448Low165.89KVolume0.470Open0.452Pre Close75.61KTurnover0.55%Turnover Ratio0.11P/E (Static)31.87MShares3.28052wk High7.06P/B13.78MFloat Cap0.25752wk Low--Dividend TTM30.04MShs Float888.800Historical High--Div YieldTTM4.82%Amplitude0.257Historical Low0.455Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the issue of a new Chinese patent Notice of Allowance covering opaganib[1] as
RedHill Biopharma Advances COVID-19 Antiviral Study
Express News | RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study Of RHB-107 (Upamostat), The Study Is Expected To Be Completed By The End Of 2024
RedHill Biopharma Full Year 2023 Earnings: EPS: US$4.00 (Vs US$46.29 Loss in FY 2022)
RedHill Biopharma's Strategic Pivot and Financial Turnaround
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
Selected for evaluation by two U.S. government countermeasures programs for Acute Radiation Syndrome (ARS) and Sulfur Mustard exposure.
Comments
This novel therapeutic agent, designed for the treatment of Ebola Virus Disease among other potential indications, now enjoys patent protection in China through 2035.
For the pharmaceutical industry and global public health, RedHill Biopharma Ltd. (NASDAQ: RDHL), a specialty biopharmaceutical company based in Tel-Aviv, Israel, and Raleigh, North Carolina, has announced the issuance of a new Chinese paten...
For the pharmaceutical industry and global public health, RedHill Biopharma Ltd. (NASDAQ: RDHL), a specialty biopharmaceutical company based in Tel-Aviv, Israel, and Raleigh, North Carolina, has announced the issuance of a new Chinese paten...
$Redhill Biopharma(RDHL.US$ RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
Benzinga· 9 mins ago
RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the issue of a new Chinese patent Notice of Allowance covering opaganib[1] as a therapyg for inhibition of single-stranded RNA virus replication (notably Ebola Disease Virus) from the Chinese National Intellectual Property Administration (...
Benzinga· 9 mins ago
RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the issue of a new Chinese patent Notice of Allowance covering opaganib[1] as a therapyg for inhibition of single-stranded RNA virus replication (notably Ebola Disease Virus) from the Chinese National Intellectual Property Administration (...
$Redhill Biopharma(RDHL.US$ RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study Of RHB-107 (Upamostat), The Study Is Expected To Be Completed By The End Of 2024
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg